Seres Therapeutics, Inc. announced the appointment of Eric D. Shaff to the additional role of Chief Operating Officer. Mr. Shaff has been Executive Vice President and Chief Financial Officer since joining the company in November 2014, and he will continue to retain both positions. Mr. Shaff has served as Seres’ Chief Financial Officer, Executive Vice President and Treasurer since November 2014. Mr. Shaff also serves on the Board of Directors for Sigilon Therapeutics and has extensive experience in the biotechnology field, having worked at Momenta Pharmaceuticals and Genzyme Corporation, where he was Vice President of Finance for the Personalized Genetic Health division.